Measuring metabolic activity in prostate cancer bone metastases using advanced MRI techniques
Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring
This study is testing a new type of MRI that uses a special substance to see how well prostate cancer treatments are working in bone metastases, helping doctors spot early signs of success or resistance to therapy so they can better care for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10983759 on NIH RePORTER |
What this research studies
This research investigates a novel imaging technique using hyperpolarized 13C-pyruvate MRI to measure metabolic activity in bone metastases from prostate cancer. The goal is to provide a more accurate and timely assessment of how well patients are responding to targeted therapies. By quantifying the conversion rates of pyruvate to lactate, the study aims to identify early signs of treatment effectiveness or resistance. This approach could lead to improved monitoring of treatment responses, ultimately enhancing patient care and outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced prostate cancer who have developed bone metastases.
Not a fit: Patients with early-stage prostate cancer or those without bone metastases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective monitoring of treatment responses in prostate cancer patients, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise with similar imaging techniques, suggesting potential for success in this novel application.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Vigneron, Daniel B — University of California, San Francisco
- Study coordinator: Vigneron, Daniel B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.